NCT05255822

INNA-051 Influenza Challenge Study

Phase 2a Study in Healthy Adult Participants Pre-treated With INNA-051 and Challenged With Influenza Virus

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 123 (actual)
• Sponsor: ENA Respiratory Pty Ltd · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in healthy adults, administered prior to administration of an influenza challenge virus. This study will evaluate 2 active dose levels of INNA-051 and placebo.

Detailed description

Healthy participants will be administered 2 doses on INNA-051 intra-nasally and subsequently administered influenza virus as a challenge. Participants will be quarantined for 8 days. Study assessments will be performed during this period and they will monitored for symptoms of influenza infection.

Conditions

• Influenza Prophylaxis

Interventions

Type	Name	Description
DRUG	INNA-051	Liquid for intra-nasal administration
OTHER	Placebo	Liquid for intra-nasal administration

Timeline

• Start date: 2022-02-28
• Primary completion: 2022-08-23
• Completion: 2022-08-23
• First posted: 2022-02-25
• Last updated: 2023-01-18

Locations

1 site across 1 country: United Kingdom